Described are medical devices including expandable tubular bodies configured to be implanted into a lumen, wherein the outer surface of the expandable tubular bodies are coupled to a polymer(s).

Described are medical devices including expandable tubular bodies configured to be implanted into a lumen, wherein the outer surface of the expandable tubular bodies are coupled to a polymer(s).

Medical articles formed from a polyurethane-based resin including a modifying oligomer provide enhanced properties. A modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by a diisocyanate, a polyglycol, and a diol chain extender has at least one, preferably two, alcohol moieties (COH) and a functional moiety. Exemplary modifying oligomers are: a diol-containing perfluoropolyether incorporated into the backbone, a monofunctional polysiloxane (e.g., monodialcohol-terminated polydimethylsiloxane) incorporated as the side chain, and combinations thereof. Medical articles herein are self-lubricating and/or anti-fouling.

The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan.

The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan.

Methods are disclosed which combine electrospinning and a sacrificial template, such as with additive manufacturing (AM), to produce fibrous microvascular scaffolds which are biodegradable, porous, and easily handled. In one example, a process for fabricating a fibrous network construct is disclosed. The method includes electrospinning a first layer of fibrous material; printing a micropatterned sacrificial template; transferring the micropatterned sacrificial template onto the electrospun fibers; electrospinning a second layer of fibrous biomaterial onto the micropatterned sacrificial template thereby encapsulating the template and generating a construct with two layers; and removing the sacrificial template, producing a fibrous construct with channels or microstructures formed therein. Also disclosed are fibrous constructs and scaffolds produced by the provided methods.

Disclosed is a high anticoagulation ECMO and extracorporeal circulation consumable, which include the following preparation methods: S1, aminating the surface of ECMO blood circulation device and extracorporeal circulation consumables; S2, activating heparin groups; S3, heparinizing the ECMO blood circulation device and extracorporeal circulation consumables; S4, modification of enhancer. The application can produce a novel high anticoagulation extracorporeal circulation tube with low price and high biocompatibility, which expands the application in clinic.

An occlusive implant includes an expandable framework that is configured to shift between a collapsed configuration and an expanded configuration. An occlusive member is disposed along at least a portion of the expandable framework. At least part of the occlusive implant is configured to repel fibrinogen. In some cases, the occlusive implant may be configured for placement within a left atrial appendage (LAA) of a patient's heart.

An object of the present invention is to provide a surface treatment agent that is excellent in antithrombogenicity and biocompatibility and has higher hydrophilicity compared to conventional medical materials. The present invention is an antithrombogenic material containing a (meth)acrylate copolymer consisting of a hydrophobic (meth)acrylate and a hydrophilic (meth)acrylate, in which the hydrophobic (meth)acrylate is a silicone (meth)acrylate and/or an alkyl (meth)acrylate, the (meth)acrylate copolymer having a residual monomer content of 4,000 ppm or less, a reduced viscosity (?sp/c) of 0.18 dl/g or more and 3.00 dl/g or less, and being water-insoluble, and being a viscous liquid at room temperature.

An object of the present invention is to provide a surface treatment agent that is excellent in antithrombogenicity and biocompatibility and has higher hydrophilicity compared to conventional medical materials. The present invention is an antithrombogenic material containing a (meth)acrylate copolymer consisting of a hydrophobic (meth)acrylate and a hydrophilic (meth)acrylate, in which the hydrophobic (meth)acrylate is a silicone (meth)acrylate and/or an alkyl (meth)acrylate, the (meth)acrylate copolymer having a residual monomer content of 4,000 ppm or less, a reduced viscosity (?sp/c) of 0.18 dl/g or more and 3.00 dl/g or less, and being water-insoluble, and being a viscous liquid at room temperature.